Brief: Compass Therapeutics posts Q2 basic EPS USD -0.09
03/08/2023 13:16
Aug 3 (Reuters) - Compass Therapeutics Q2 income from operations USD -13.337 million. * Q2 net income USD -11.278 million * Q2 basic EPS USD -0.09 * Q2 operating expenses USD 13.337 million
Recent news on Compass Therapeutics
See all newsBrief: Compass Announces Inducement Grants Under Nasdaq Listing Rule
US RESEARCH ROUNDUP- Allstate, Autozone, Vertex Pharmaceuticals
U.S. STOCKS ON THE MOVE-Greenland Mines, GameStop, Shopify
U.S. STOCKS ON THE MOVE-Vicor, Thor Industries, Lennar
Brief: Compass Therapeutics Provides Regulatory Update On Tovecimig In Biliary Tract Cancer Following FDA Feedback